-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ubidecarenone in Brain Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ubidecarenone in Brain Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ubidecarenone in Brain Cancer Drug Details: Ubidecarenone is under development for...
-
Product Insights
NewGallbladder Cancer – Drugs In Development, 2024
Empower your strategies with our Gallbladder Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Gallbladder cancer symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine, and weight loss. Risk factors include overweight, age, family history, gallstones, gender, and choledochal cysts. Treatment includes surgery, chemotherapy, and radiation therapy. The Gallbladder Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with...
-
Product Insights
NewGastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024
Empower your strategies with our Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal (GE) junction carcinomas are malignancies occurring at the point where the esophagus meets the stomach. Typically classified as adenocarcinomas or squamous cell carcinomas, adenocarcinomas are more prevalent. Risk factors include chronic gastroesophageal reflux disease (GERD), obesity, and smoking. Symptoms often manifest in advanced stages, including difficulty swallowing, weight loss, and abdominal pain. Diagnosis involves endoscopic procedures and imaging studies....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Solid Tumor Drug Details: DFP-14927 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-90011 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-90011 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-90011 in Solid Tumor Drug Details: BMS-90011 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radgocitabine in Refractory Acute Myeloid Leukemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radgocitabine in Refractory Acute Myeloid Leukemia Drug Details: Radgocitabine (DFP-10917) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-11207 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DFP-11207 in Gastric Cancer Drug Details:DFP-11207 is under development for the treatment of solid tumors including...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TS-23 in Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TS-23 in Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TS-23 in Ischemic Stroke Drug Details: DS-9231 (TS23) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIC-Lx in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIC-Lx in Kidney Transplant Rejection report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...